Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

said in a news release. Santagostino spent about six years at Lonza as the company's head of cell and gene technologies.

As a leading CDMO for bioconjugates, Lonza has produced over 1,000 cGMP batches for more than 70 programs since 2006. Lonza offers customers a fully integrated solution, spanning design and lead ...

Cellares, the world's first Integrated Development and Manufacturing Organization (IDMO), and a leader in automated cell therapy manufacturing, has appointed Ossama Eissa, former executive at Novartis ...

By using targeted delivery to cancer cells while limiting toxicity to healthy tissues, they are fulfilling their therapeutic and commercial potential by transforming treatment options and bringing ...

Lonza LONN-1.18%decrease; red down pointing triangle said it expected accelerated sales growth in the fourth quarter on the back of the timing of product releases and the ramp-up of its new ...

Emerging from the rough waters of the CDMO industry with a new chief executive at the helm, AGC Biologics is on a mission to reinvent itself as a manufacturing partner defined by friendliness and e | ...

Lonza has continued to adapt to the evolving ADC landscape, including the recent addition of a highly potent vial fill ...

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...